Phase II Randomized Study of Pembrolizumab With or Without Epigenetic Modulation With CC-486 in Patients With Platinum-resistant Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Latest Information Update: 15 Jun 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Pembrolizumab (Primary)
- Indications Carcinoma; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Adverse reactions; Therapeutic Use
- 17 May 2022 Status changed from completed to discontinued.
- 22 Sep 2021 Status changed from active, no longer recruiting to completed.
- 06 Apr 2021 Planned End Date changed from 31 Mar 2021 to 30 Sep 2021.